Sellas Life Sciences Group Inc
SLS2.890USD
+0.250+9.47%
Market hours （ET）Quotes delayed by 15 min
361.48MMarket Cap
LossP/E TTM
More Details of Sellas Life Sciences Group Inc Company
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Sellas Life Sciences Group Inc Info
Ticker SymbolSLS
Company nameSellas Life Sciences Group Inc
IPO dateMar 12, 2008
CEOStergiou (Angelos M)
Number of employees15
Security typeOrdinary Share
Fiscal year-endMar 12
Address7 Times Square
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone16462005278
Websitehttps://www.sellaslifesciences.com/
Ticker SymbolSLS
IPO dateMar 12, 2008
CEOStergiou (Angelos M)
Company Executives of Sellas Life Sciences Group Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
93.80K
+208.55%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Dr. David A. Scheinberg, M.D., Ph.D.
Dr. David A. Scheinberg, M.D., Ph.D.
Independent Director
Independent Director
10.58K
-38.05%
Mr. John W. Varian
Mr. John W. Varian
Independent Chairman of the Board
Independent Chairman of the Board
10.40K
-38.46%
Name
Name/Position
Position
Shareholding
Change
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
93.80K
+208.55%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.80%
Anson Funds Management LP.
4.24%
BlackRock Institutional Trust Company, N.A.
3.64%
Marshall Wace LLP
1.66%
Geode Capital Management, L.L.C.
1.59%
Other
84.07%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.80%
Anson Funds Management LP.
4.24%
BlackRock Institutional Trust Company, N.A.
3.64%
Marshall Wace LLP
1.66%
Geode Capital Management, L.L.C.
1.59%
Other
84.07%
Shareholder Types
Shareholders
Proportion
Investment Advisor
11.84%
Investment Advisor/Hedge Fund
5.39%
Hedge Fund
5.29%
Research Firm
0.51%
Individual Investor
0.26%
Bank and Trust
0.09%
Pension Fund
0.04%
Insurance Company
0.03%
Other
76.55%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
135
27.86M
26.46%
+4.71M
2025Q2
100
16.82M
16.86%
+5.40M
2025Q1
95
15.37M
15.79%
+4.85M
2024Q4
82
6.32M
8.71%
-3.29M
2024Q3
79
5.54M
8.62%
-2.91M
2024Q2
81
6.60M
15.25%
-2.78M
2024Q1
80
10.46M
22.59%
+5.00M
2023Q4
78
5.95M
19.06%
+1.91M
2023Q3
79
3.15M
11.52%
-1.61M
2023Q2
83
3.51M
12.82%
-1.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
6.65M
6.32%
+3.82M
+134.38%
Jun 30, 2025
Anson Funds Management LP.
275.00K
0.26%
-7.30M
-96.37%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.17M
3.96%
+3.73M
+855.11%
Jun 30, 2025
Marshall Wace LLP
2.72M
2.58%
+2.70M
+23549.97%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.20M
2.09%
+1.38M
+168.20%
Jun 30, 2025
State Street Investment Management (US)
1.11M
1.06%
+835.68K
+301.66%
Jun 30, 2025
Nuveen LLC
971.33K
0.92%
+971.33K
--
Jun 30, 2025
Susquehanna International Group, LLP
1.49M
1.41%
+800.98K
+116.30%
Jun 30, 2025
Northern Trust Investments, Inc.
683.13K
0.65%
+518.74K
+315.55%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
538.78K
0.51%
+510.23K
+1787.21%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.04%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Vanguard US Momentum Factor ETF
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.04%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Sellas Life Sciences Group Inc?
The top five shareholders of Sellas Life Sciences Group Inc are:
The Vanguard Group, Inc. holds 6.65M shares, accounting for 6.32% of the total shares.
Anson Funds Management LP. holds 275.00K shares, accounting for 0.26% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.17M shares, accounting for 3.96% of the total shares.
Marshall Wace LLP holds 2.72M shares, accounting for 2.58% of the total shares.
Geode Capital Management, L.L.C. holds 2.20M shares, accounting for 2.09% of the total shares.
The Vanguard Group, Inc. holds 6.65M shares, accounting for 6.32% of the total shares.
Anson Funds Management LP. holds 275.00K shares, accounting for 0.26% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.17M shares, accounting for 3.96% of the total shares.
Marshall Wace LLP holds 2.72M shares, accounting for 2.58% of the total shares.
Geode Capital Management, L.L.C. holds 2.20M shares, accounting for 2.09% of the total shares.
What are the top three shareholder types of Sellas Life Sciences Group Inc?
The top three shareholder types of Sellas Life Sciences Group Inc are:
The Vanguard Group, Inc.
Anson Funds Management LP.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Anson Funds Management LP.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Sellas Life Sciences Group Inc (SLS)?
As of 2025Q3, 135 institutions hold shares of Sellas Life Sciences Group Inc, with a combined market value of approximately 27.86M, accounting for 26.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 9.60%.
What is the biggest source of revenue for Sellas Life Sciences Group Inc?
In --, the -- business generated the highest revenue for Sellas Life Sciences Group Inc, amounting to -- and accounting for --% of total revenue.
